{"filing":{"accession_number":"0001104659-26-076857","cik":"0001583107","ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"tm2618538d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926076857/tm2618538d1_8k.htm"},"events":[{"id":13264,"run_id":11773,"accession_number":"0001104659-26-076857","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The disclosure centers on the termination of Áine Miller, Senior Vice President and Head of Ireland Office, effective November 15, 2026, pursuant to a compromise agreement entered into on June 19, 2026 in connection with the Company's March 2026 restructuring. While the filing also mentions compensatory arrangements (RSU grant and pension contribution), the principal disclosed action is the executive's departure from the Company.","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10360,"accession_number":"0001104659-26-076857","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on the termination of Áine Miller, Senior Vice President and Head of Ireland Office, effective November 15, 2026, pursuant to a compromise agreement entered into on June 19, 2026 in connection with the Company's March 2026 restructuring. While the filing also mentions compensatory arrangements (RSU grant and pension contribution), the principal disclosed action is the executive's departure from the Company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:03:54.964836+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10360,"accession_number":"0001104659-26-076857","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on the termination of Áine Miller, Senior Vice President and Head of Ireland Office, effective November 15, 2026, pursuant to a compromise agreement entered into on June 19, 2026 in connection with the Company's March 2026 restructuring. While the filing also mentions compensatory arrangements (RSU grant and pension contribution), the principal disclosed action is the executive's departure from the Company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:03:54.964836+00:00","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-06-23"}]}